When does Keytruda’s patent expire (by jurisdiction)?
Keytruda (pembrolizumab) does not have a single, universal “expiration date.” Patent coverage depends on the specific patent(s), the country, and whether you mean the filing/term expiration date or the end of regulatory exclusivities (which can extend market protection beyond patents). The provided information here does not include the patent numbers, countries, or any specific expiration dates for Keytruda, so the exact “when” cannot be stated from the source material available to me.
What details are needed to give a specific expiration date?
To answer “specifically” with a date, you typically need at least one of the following:
- The country/region (e.g., US, EU, UK, Canada, Japan).
- The patent number(s) covering Keytruda (and which aspect they cover: molecule, specific methods of use, formulations, etc.).
- Whether you want the end of patent term (often tied to filing dates and adjustments) or the end of data/exclusivity protections granted by regulators.
Is it possible that exclusivity extends beyond the patent term?
Yes. Even if a patent on pembrolizumab expires, regulatory exclusivities and other forms of protection can delay entry of competitors in many jurisdictions. Determining the practical “earliest launch date” for potential biosimilars/generics depends on both patent status and regulatory exclusivities.
If you tell me the country, I can narrow to the exact date
If you reply with the jurisdiction you care about (for example: “US only” or “EU only”) and whether you mean “patent term expiration” versus “regulatory exclusivity end,” I can give the most specific expiration timing based on the relevant sources.